विटामिन K के इंटरैक्शन

WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY and INCREASED RISK OF BLEEDING WITH CONCOMITANT USE OF VITAMIN K ANTAGONISTS Increased risk of serious adverse reactions or death in patients with complete DPD deficiency • Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary. (कैपेसिटाबिन लेबल, बॉक्स्ड चेतावनी)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (फेनिटोइन लेबल, चेतावनियां और सावधानियां)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (फॉस्फेनिटोइन लेबल, चेतावनियां और सावधानियां)

Do not administer agents that enhance the risk of hemorrhage with fondaparinux sodium unless essential for the management of the underlying condition, such as vitamin K antagonists for the treatment of VTE. (फोंडापैरिनक्स लेबल, चेतावनियां और सावधानियां)

Patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage). (ब्यूटाल्बिटल, एस्पिरिन और कैफीन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (रिफैम्पिसिन लेबल, चेतावनियां)

विटामिन K वारफेरिन के एंटीकोएगुलेंट असर को कम करता है; सप्लीमेंट या खानपान से इसके सेवन में अचानक बदलाव INR को बिगाड़ सकते हैं। (NIH Office of Dietary Supplements, Vitamin K)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (एडोक्साबैन लेबल, चेतावनियां और सावधानियां)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (एपिक्साबैन लेबल, चेतावनियां और सावधानियां)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (ऑर्लिस्टैट लेबल, दवाओं के इंटरैक्शन)

Vitamin K or Fat-Soluble Vitamin Deficiencies: Colesevelam hydrochloride may decrease absorption of fat-soluble vitamins. (कोलेसेवेलम लेबल, चेतावनियां और सावधानियां)

Warfarin and oral anticoagulants Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. (क्विनीन लेबल, दवाओं के इंटरैक्शन)

For patients with APS (especially those who are triple-positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (डैबिगैट्रान लेबल, चेतावनियां और सावधानियां)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (नियोमाइसिन लेबल, दवाओं के इंटरैक्शन)

Increased prothrombin time has been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Anticoagulants (oral) : Due to the potential inhibition of vitamin K activity by propylthiouracil, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. (प्रोपाइलथायोयूरेसिल लेबल, दवाओं के इंटरैक्शन)

Some patients had serious bleeding including intracranial, retroperitoneal, and gastrointestinal requiring blood transfusion and/or administration of vitamin K. (बाइकैलुटामाइड लेबल, चेतावनियां और सावधानियां)

This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, चेतावनियां और सावधानियां)

Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers… (मेथिमाज़ोल लेबल, दवाओं के इंटरैक्शन)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (रिवारोक्साबैन लेबल, चेतावनियां और सावधानियां)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (लेवोथायरोक्सिन और लियोथायरोनिन लेबल, दवाओं के इंटरैक्शन)

In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. (सुगैमाडेक्स लेबल, चेतावनियां और सावधानियां)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (सेफाज़ोलिन लेबल, चेतावनियां और सावधानियां)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. (सेफिक्सिम लेबल, चेतावनियां और सावधानियां)

Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated. (सेफेपिम लेबल, चेतावनियां और सावधानियां)

Prothrombin time should be monitored and exogenous vitamin K administered as indicated. (सेफोटेटन लेबल, चेतावनियां)

Patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during Ceftriaxone for Injection and Dextrose Injection treatment. (सेफ्ट्रिएक्सोन लेबल, चेतावनियां और सावधानियां)

Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. (प्रिमिडोन लेबल, चेतावनियां)

Cutaneous Reactions Parenteral administration of vitamin K replacements (including phytonadione injectable emulsion) may cause cutaneous reactions. (फाइटोमेनाडायोन (विटामिन K1) लेबल, चेतावनियां और सावधानियां)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (मिथाइलएर्गोमेट्रिन लेबल, चेतावनियां)